Inflammatory Cytokines and type 2 diabetes

authors:

avatar Mohammad Hassan Jokar , avatar Sima Sedighi , avatar Mehrdad Aghaie ORCID , avatar Ashraf Mohamadkhani , avatar Maliheh Moradzadeh , *

Koomesh: Vol.22, issue 3; 396-403
published online: September 01, 2020
article type: Research Article
received: September 01, 2019
accepted: December 01, 2019

How To Cite Jokar M H , Sedighi S , Aghaie M, Mohamadkhani A, Moradzadeh M. Inflammatory Cytokines and type 2 diabetes. koomesh. 2020;22(3):e153194. 

Abstract

Inflammatory cytokines increase in patients with type 2 diabetes (T2D) and metabolic syndrome. This review focuses on inflammatory cytokines such as C-reactive protein (CRP), tumor necrosis factor (TNF-α), and adiponectin, a cytokine produced by adipose tissue and associated with insulin sensitivity. Despite the major role of cytokines in the development of T2D, in the case of adiponectin still is a matter of debate as the best strategy to change proper inflammatory response.

References

  • 1.

    Ross R. Atherosclerosisan inflammatory disease. N Engl J Med 1999; 340: 115-126.

  • 2.

    Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-E533.

  • 3.

    Haji-Arabi E, Nobahar M, Ghorbani R. Relationship between depression and knowledge about diabetes with the amount of self-care in patients with type 2 diabetes. Koomesh 2018; 210-220. (Persian).

  • 4.

    Mohammadi H, Avandi SM. Effect of eight weeks resistance training with ginger supplementation on malondialdehyde and body compostion index in type 2 diabetes patients. Koomesh 2019; 21: 73-82. (Persian).

  • 5.

    Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154-1162.

  • 6.

    Ekmekci H, Ekmekci OB. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost 2006; 12: 163-168.

  • 7.

    Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone Jr MA, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718.

  • 8.

    Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.

  • 9.

    Santos MGd, Pegoraro M, Sandrini F, and Macuco EC. Risk factors for the development of atherosclerosis in childhood and adolescence. Arq Bras Cardiol 2008; 90: 301-308.

  • 10.

    Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.

  • 11.

    Cawthorn WP, Sethi JK. TNF and adipocyte biology. FEBS letters 2008; 582: 117-131.

  • 12.

    Murphy K, Travers P, Walport M. Janeways immunobiology. Garland science. New York 2008.

  • 13.

    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acidinduced insulin resistance. J Clin Invest 2006; 116: 3015-3025.

  • 14.

    Ungvari Z, Sonntag WE, Csiszar A. Mitochondria and aging in the vascular system. J Mol Med 2010; 88: 1021-1027.

  • 15.

    Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.

  • 16.

    Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009; 8: 18-30.

  • 17.

    Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008; 8: 923.

  • 18.

    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.

  • 19.

    Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99: 10730-10735.

  • 20.

    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721.

  • 21.

    Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451: 904.

  • 22.

    Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol 2008; 198: 127-134.

  • 23.

    Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity: symposium on Frontiers in adipose tissue biology. Proc Nutr Soc 2009; 68: 370-377.

  • 24.

    Peppa M, Stavroulakis P, Raptis SA. Advanced glycoxidation products and impaired diabetic wound healing. Wound Repair Regen 2009; 17: 461-472.

  • 25.

    Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070.

  • 26.

    Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010; 2: 1184-1195.

  • 27.

    Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002; 99: 15596-15601.

  • 28.

    Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55: 229-238.

  • 29.

    Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006; 1084: 89-117.

  • 30.

    Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive proteinmediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.

  • 31.

    Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes 2001; 25: 1416.

  • 32.

    Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.

  • 33.

    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.

  • 34.

    Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 12: 425.

  • 35.

    Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.

  • 36.

    De Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002; 317: 1-15.

  • 37.

    Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et all. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674.

  • 38.

    Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. Vasc Med 2008; 13: 113-121.

  • 39.

    Zacho J, Tybjrg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-1908.

  • 40.

    Pourahmadi M, Erfanian S, Moradzadeh M, Jahromi AS. Non-association between rs7903146 and rs12255372 polymorphisms in transcription factor 7-like 2 gene and type 2 diabetes mellitus in Jahrom City, Iran. Diabetes Metab J 2015; 39: 512-517. (Persian).

  • 41.

    Mohammadi F, Pourahmadi M, Mosalanejad M, Jamali H, Ghobadifar MA, Erfanian S. Association of estrogen receptor genes PvuII and XbaI polymorphisms with type 2 diabetes mellitus in the inpatient population of a hospital in southern Iran. Diabetes Metab J 2013; 37: 270-277.

  • 42.

    Erfanian S, Moradzadeh M, Solhjoo K, Jahromi AS. Data describing the association between rs266729 polymorphism inadiponectin promoter gene and Type 2 Diabetes Mellitus. Data in Brief 2016; 9: 1138-1140.

  • 43.

    Erfanian S, Shakeri M, Shakeri H, Rahmanian Z, Sohrabi A, Jahromi AS, et al. Association of rs1883832 SNP in Kozak Region of CD40 Gene with Diabetes Mellitus Type 2: A Case Control Study. J Int Trans Med 2019; 7: 25-28. (Persian).

  • 44.

    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.

  • 45.

    Stephens JM, Lee J, Pilch PF. Tumor necrosis factor--induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-976.

  • 46.

    Wang B, Trayhurn P. Acute and prolonged effects of TNF- on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflgers Archiv 2006; 452: 418-427.

  • 47.

    Jovinge S, Hamsten A, Tornvall P, Proudler A, Bvenholm P, Ericsson CG, et al. Evidence for a role of tumor necrosis factor in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998; 47: 113-118.

  • 48.

    Celec P. Nuclear factor kappa Bmolecular biomedicine: the next generation. Biomed Pharmacother 2004; 58: 365-371.

  • 49.

    Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107: 1460-1462.

  • 50.

    Qin B, Anderson RA, Adeli K. Tumor necrosis factor- directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1120-G1129.

  • 51.

    Bastard JP, Jardel C, Bruckert E, Vidal H, Hainque B. Variations in plasma soluble tumour necrosis factor receptors after dietinduced weight loss in obesity. Diabetes Obes Metab 2000; 2: 323-326.

  • 52.

    Sharman MJ, Volek JS. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci 2004; 107: 365-369.

  • 53.

    Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-B signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.

  • 54.

    Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.

  • 55.

    Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.

  • 56.

    Coughlin CC, Finck BN, Eagon JC, Halpin VJ, Magkos F, Mohammed BS, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity 2007; 15: 640-645.

  • 57.

    Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.

  • 58.

    Cnop M, Havel PJ, Utzschneider K, Carr D, Sinha M, Boyko E, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.

  • 59.

    Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941.

  • 60.

    Yamauchi T, Kamon J, Minokoshi Ya, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288.

  • 61.

    Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 2003; 111: 246-250.

  • 62.

    Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMPactivated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574: 41-53.

  • 63.

    Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-187.

  • 64.

    Ng TW, Watts GF, Barrett PHR, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007; 30: 2945-2950.

  • 65.

    Simpson KA, Singh MAF. Effects of exercise on adiponectin: a systematic review. Obesity 2008; 16: 241-256.

  • 66.

    Egger G, Dixon J. Should obesity be the main game? Or do we need an environmental makeover to combat the inflammatory and chronic disease epidemics? Obes Rev 2009; 10: 237-249.

  • 67.

    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.

  • 68.

    Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860.

  • 69.

    Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-1050.

  • 70.

    Rnn SG, Billestrup N, Mandrup-Poulsen T. Diabetes and suppressors of cytokine signaling proteins. Diabetes 2007; 56: 541-548.

  • 71.

    Yuan G, Chen X, Ma Q, Qiao J, Li R, Li X, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007; 194: 275-281.

  • 72.

    Coppack S, Evans R, Fisher R, Frayn K, Gibbons G, Humphreys S, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992; 41: 264-272.

  • 73.

    Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.

  • 74.

    Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22: 423-436.

  • 75.

    Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004; 80: 1029-1035.

  • 76.

    Heidemann C, Hoffmann K, Spranger J, Klipstein-Grobusch K, Mhlig M, Pfeiffer A, et al. A dietary pattern protective against type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)Potsdam Study cohort. Diabetologia 2005; 48: 1126-1134.

  • 77.

    Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns and markers of systemic inflammation among Iranian women. J Nutr 2007; 137: 992-998.

  • 78.

    Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-1446.

  • 79.

    Wannamethee SG, Whincup PH, Thomas MC, Sattar N. Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk. Diabetes Care 2009; 32: 1823-1825.

  • 80.

    Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ. Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma. J Nutr 2010; 140: 587-594.

  • 81.

    Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM, et al. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2006; 83: 1369-1379.

  • 82.

    Moradzadeh M, Roustazadeh A, Tabarraei A, Erfanian S, Sahebkar A. Epigallocatechin3gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PMLRAR and HDAC1. Phytother Res 2018; 32: 471-479.

  • 83.

    Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol 2006; 48: 677-685.

  • 84.

    Herder C, Peltonen M, Koenig W, Stfels K, Lindstrm J, Martin S, et al. Anti-inflammatory effect of lifestyle changes in the Finnish diabetes prevention study. Diabetologia 2009; 52: 433-442.

  • 85.

    Puglisi MJ, Vaishnav U, Shrestha S, Torres-Gonzalez M, Wood RJ, Volek JS, et al. Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids Health Dis 2008; 7: 14.

  • 86.

    Zern T, Wood R, Greene C, West K, Liu Y, Aggarwal D, et al. Grape polyphenols lower plasma lipids and apolipoproteins associated with increased risk for cardiovascular disease in pre and post-menopausal women. J Nutr 2005; 135: 1911-1947.